{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 26,
  "pageCount": 41,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a numbered list format to highlight progress, including financial, manufacturing, partnership, clinical, and regulatory milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/26",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.06,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "Note: Photo credit: CDC/Alissa Eckert, MSMI; Dan Higgins, MAM. 1 Valneva announces major COVID-19 vaccine partnership with U.K. Government. 2 Valneva in advanced discussion with European Commission to supply up to 60m doses of Inactivated, Adjuvanted COVID-19 vaccine candidate. 3 Valneva commences manufacturing of its Inactivated, Adjuvanted COVID-19 vaccine, completes Phase 1/2 study recruitment. 4 Valneva and Dynavax announce commercial supply agreement for Inactivated, Adjuvanted COVID-19 vaccine. 5 Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37ec098b-c23c-4ad4-acdf-73a904d40de7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.18,
        "x": 0.06,
        "y": 0.24
      },
      "kind": "image",
      "text": "SARS-CoV-2 virus illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "665a0704-d5be-438f-8839-6a0116faec4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.22,
        "y": 0.24
      },
      "kind": "list",
      "text": "1. UK government deal worth up to €1.4 billion with development and manufacturing funding; ongoing dialogue with other potential customers\n2. Program acceleration enabled through use of Valneva’s FDA-registered facility in UK; commercial manufacturing commenced January 2021\n3. Combines Valneva’s proven approach of inactivated vaccines with Dynavax’s advanced CpG 1018 adjuvant\n4. Phase 1/2 clinical trial results reported, Phase 3 initiated\n5. Regulatory submission to MHRA planned in autumn 2021, deliveries thereafter, subject to approval",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12515448-d27c-4231-8fb8-872c3d48ff93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "VLA2001 – The Only Inactivated Vaccine in Clinical Development in Europe : Adjuvanted with CpG1018",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eec9f9ff-d037-4edb-9dc1-a229f9038e1c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "6e4abec7-a853-4251-9bd4-4e7dd8e5878d",
      "evidence": "list/bullet: 1. UK government deal worth up to €1.4 billion with development and manufacturing funding; ongoing dialogue with other potential customers",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "cfd10062-950f-44e1-a5ea-ef312e908c70",
      "evidence": "Numbered list used to present sequential or categorical milestones.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}